


Vadimezan

Chemical Properties

CAS No. :	117570-53-3
Formula:	C17H14O4
Molecular Weight:	282.29
Storage:	Powder: -20°C for 3 years In solvent: -80°C for 1 year Actual storage temperature shall be subject to the COA.



Biological Description

Description	Vadimezan (DMXAA) is a vascular disrupting agent, a murine STING agonist, and an inducer of cytokines such as type I IFN. Vadimezan has antitumor activity and induces a rapid cessation of blood flow in tumors without affecting blood flow in normal tissues.
Targets(IC50)	IFNAR, Influenza Virus, STING, VDA
In vitro	<p>METHODS: DLBCL cells LY1 and LY3 were treated with Vadimezan (0-300 μM) for 24 h. Cell viability was measured by CCK-8 assay.</p> <p>RESULTS: Vadimezan treatment decreased the viability of DLBCL cells in a dose-dependent manner, with IC50s of 177 μM and 165 μM for LY1 and LY3, respectively. [1]</p> <p>METHODS: Human lung cancer cells A549 were treated with Vadimezan (0.1-1 μM) for 24 h. The expression levels of target proteins were detected by Western Blot.</p> <p>RESULTS: Vadimezan induced a significant increase in the cytoplasmic level of cytochrome c and the activation of caspase 3, which ultimately led to apoptosis and death of A549 cells. [2]</p>
In vivo	<p>METHODS: To assay antitumor activity in vivo, Vadimezan (20 mg/kg) and BMS1166 (250 μg/mL) were injected intraperitoneally into Balb/c nude mice bearing DLBCL tumor LY1 once daily for eight days.</p> <p>RESULTS: Vadimezan and BMS1166 acted at effective concentrations. The combination treatment significantly inhibited the growth of GCB-like DLBCL cells compared to monotherapy. [1]</p> <p>METHODS: To assay antitumor activity in vivo, Vadimezan (25,5,5,25 mg/kg; 25,0,0,25 mg/kg; 25,25,25,25 mg/kg) was administered intraperitoneally every three days to C57BL/6j mice bearing mouse mesothelioma AE17 for four doses.</p> <p>RESULTS: In group 1, 2/4 mice were cured, of which 2/4 showed long-term survival, but toxicity problems were observed. A better, less toxic response was observed in Group 2, with all four mice cured and showing long-term survival. In group 3, only 1 mouse was cured, but none showed long-term survival, possibly due to associated toxicity issues. [3]</p>
Kinase Assay	DT-diaphorase activity and kinetic analysis of enzyme inhibition : Purified DT-diaphorase enzyme activity is assayed by measuring the reduction of cytochrome c at 550 nm on a Beckman DU 650 spectrophotometer. Each assay contains cytochrome c (70 μ M), NADH (variable concentrations), purified DT-diaphorase (0.032 μ g), and menadione (variable concentrations) in a final volume of 1 mL Tris-HCl buffer (50 mM, pH 7.4) containing 0.14% BSA. The reaction is started by the addition of NADH. Rates of

Kinase Assay	reduction are calculated over the initial part of the reaction curve (30 seconds), and results are expressed in terms of μmol cytochrome c reduced/min/mg protein using a molar extinction coefficient of $21.1 \text{ mM}^{-1} \text{ cm}^{-1}$ for reduced cytochrome c. Enzyme assays are carried out at room temperature and all reactions are performed in triplicate. Inhibition of purified DT-diaphorase activity is performed by the inclusion of DMXAA (at various concentrations) in the reaction, and inhibition characteristics are determined by varying the concentration of NADH (constant menadione) or menadione (constant NADH) at several concentrations of inhibitor. K_i values are obtained by plotting $1/V$ against. The activity of DT-diaphorase in DLD-1 cells is determined by measuring the dicumarol-sensitive reduction of DCPIP at 600 nm. Briefly, DLD-1 cells in mid-exponential growth are harvested by scraping into ice-cold buffer (Tris-HCl, 25 mM, pH 7.4 and 250 mM sucrose) and sonicated on ice. Enzyme assay conditions are 2 mM NADH, 40 μM DCPIP, 20 μL of dicumarol (when required) in a final volume of 1 mL Tris-HCl (25 mM, pH 7.4) containing BSA (0.7 mg/mL). Results are expressed as the dicumarol-sensitive reduction of DCPIP using a molar extinction coefficient of $21 \text{ mM}^{-1} \text{ cm}^{-1}$. Protein levels are determined using the Bradford assay
Cell Research	DLD-1 human colon carcinoma and H460 human non-small cell lung carcinoma cells are routinely maintained as monolayer cultures in RPMI 1640 culture medium supplemented with foetal calf serum (10%), sodium pyruvate (2 mM), penicillin/streptomycin (50 IU mL ⁻¹ /50 μg mL ⁻¹) and l-glutamine (2 mM). Chemosensitivity is assessed using the MTT assay and all assays are performed under aerobic conditions. Briefly, cells are plated into each well of a 96-well culture plate and incubated overnight in an atmosphere containing 5% CO ₂ . Culture medium is completely removed from each well and replaced with medium containing a range of drug concentrations. In the case of menadione alone, the duration of drug exposure is 1 hour, after which the cells are washed twice with Hanks' balanced salt solution prior to the addition of 200 μL fresh RPMI 1640 medium to each well of the plate. In the case of DMXAA alone, the duration of drug exposure is 3 hours. Following a four-day incubation, cell survival is determined using the MTT assay. For combinations of DMXAA with menadione, cells are initially set up and a non-toxic (>95% cell survival) concentration of DMXAA is selected. Cells are then initially exposed to DMXAA (2 mM) for a period of 2 hours, following which the medium is removed and replaced with medium containing the inhibitor (DMXAA at a constant concentration of 2 mM) and menadione (at a range of drug concentrations). Following a further 7-hour incubation, cells are washed twice with Hanks' balanced salt solution prior to the addition of growth

Solubility Information

Solubility	DMSO: 7.5 mg/mL (26.57 mM), Sonication is recommended. ($< 1 \text{ mg/ml}$ refers to the product slightly soluble or insoluble)
In vivo Formulation	10% DMSO+40% PEG300+5% Tween 80+45% Saline: 0.57 mg/mL (2.02 mM), Suspension. <i>Please add the solvents sequentially, clarifying the solution as much as possible before adding the next one. Dissolve by heating and/or sonication if necessary. Working solution is recommended to be prepared and used immediately. The formulation provided above is for reference purposes only. In vivo formulations may vary and should be modified based on specific experimental conditions.</i>

Preparing Stock Solutions

	1mg	5mg	10mg
1 mM	3.5425 mL	17.7123 mL	35.4246 mL
5 mM	0.7085 mL	3.5425 mL	7.0849 mL
10 mM	0.3542 mL	1.7712 mL	3.5425 mL
50 mM	0.0708 mL	0.3542 mL	0.7085 mL

Please select the appropriate solvent to prepare the stock solution, according to the solubility of the product in different solvents. Please use it as soon as possible.

Note: The dilution table applies only to solid products. For liquid products, please calculate the stock solution based on the stated concentration and/or density.

Reference

- Cai Y, et al. Activation of STING by SAMHD1 Deficiency Promotes PANoptosis and Enhances Efficacy of PD-L1 Blockade in Diffuse Large B-cell Lymphoma. *Int J Biol Sci.* 2023 Aug 28;19(14):4627-4643.
- Zhao M, Wang B, Zhang C, et al. The DJ1-Nrf2-STING axis mediates the neuroprotective effects of Withaferin A in Parkinson's disease. *Cell Death & Differentiation.* 2021: 1-19.
- Chen C, Zhang Y, Tao M, et al. Atrial Natriuretic Peptide Attenuates Colitis via Inhibition of the cGAS-STING Pathway in Colonic Epithelial Cells. *International Journal of Biological Sciences.* 2022, 18(4): 1737-1754.
- Pan ST, et al. Proteomic response to 5,6-dimethylxanthenone 4-acetic acid (DMXAA, vadimezan) in human non-small cell lung cancer A549 cells determined by the stable-isotope labeling by amino acids in cell culture (SILAC) approach. *Drug Des Devel Ther.* 2015 Feb 17;9:937-68.
- Xu X, Huang Z, Huang Z, et al. Butyrate attenuates intestinal inflammation in Crohn's disease by suppressing pyroptosis of intestinal epithelial cells via the cGSA-STING-NLRP3 axis. *International Immunopharmacology.* 2024, 143: 113305.
- Graham PT, et al. The STING agonist, DMXAA, reduces tumor vessels and enhances mesothelioma tumor antigen presentation yet blunts cytotoxic T cell function in a murine model. *Front Immunol.* 2022 Nov 18;13:969678.
- Chen Y, Zhi Y, Zhong H, et al. Inhibition of Kv1.3 channel restrains macrophage M2 polarization and ameliorates renal fibrosis via regulating STAT6 phosphorylation. *Pharmacological Research.* 2025: 107623.
- Liu JJ, et al. *Cancer Chemother Pharmacol.* 2007, 59(5), 661-669.
- Chen C, Yan W, Zhang Y, et al. ANP Attenuates Intestinal Inflammation by Regulating STING Pathway[J]. Available at SSRN 3756807.
- Zhao M, Wang B, Zhang C, et al. The DJ1-Nrf2-STING axis mediates the neuroprotective effects of Withaferin A in Parkinson's disease[J]. *Cell Death & Differentiation.* 2021: 1-19.

Inhibitor · Natural Compounds · Compound Libraries · Recombinant Proteins

This product is for Research Use Only · Not for Human or Veterinary or Therapeutic Use

Tel: 781-999-4286 E_mail: info@targetmol.com Address: 34 Washington Street, Wellesley Hills, MA 02481